Saturday 17 October 2026
Export DNA’s income statement to Excel — free account
Ginkgo Bioworks Holdings, Inc.
In the quarter to June 2026, revenue fell 48.5%, EPS grew 31.8% and free cash flow fell 16.4%, each against the same quarter a year earlier.
10.27
1.49
−12.67%
Follow DNA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 4 | 2 |
| (50.02%) | (51.08%) | (55.82%) | (56.29%) | ||
| (25.43%) | (25.05%) | (26.17%) | (26.19%) | ||
ROIC |
(212.39%) | (229.21%) | (274.12%) | (161.94%) | |
Return on Tangible Assets |
(59.84%) | (57.57%) | (61.70%) | (69.74%) | |
Average Days of Receivables |
50.99 | 52.03 | 48.87 | 35.87 | |
Free Cash Flow per Share |
(3.36) | (3.21) | (2.81) | (2.81) | |
Free Cash Flow |
(187.13) | (178.15) | (167.63) | (174.23) | |
Capital Expenditures |
(21.31) | (7.09) | (1.40) | (3.98) | |
| Other line items | |||||
Cash ROIC |
(18.32%) | (19.13%) | (20.53%) | (24.12%) | |
Accounts Receivable Turnover |
6.91 | 7.29 | 6.38 | 7.33 | |
Accounts Payable Turnover |
2.42 | 3.80 | 3.33 | 4.07 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
122.50 | 82.10 | 129.46 | 82.58 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
168.71% | 143.27% | 147.14% | 162.82% | |
Selling, General and Administrative Expense of Revenue |
110.56% | 107.72% | 119.81% | 133.81% | |
Share Based Compensation of Revenue |
50.66% | 47.92% | 52.85% | 51.96% | |
Operating CF/Net income |
0.49 | 0.55 | 0.55 | 0.59 | |
Depreciation/Fixed assets |
0.35 | 0.33 | 0.33 | 0.32 | |
Capex/Depreciation |
(0.35) | (0.13) | (0.03) | (0.08) | |
Revenue per Share |
2.88 | 3.07 | 2.54 | 2.13 | |
Operating CF per Share |
(2.98) | (3.08) | (2.79) | (2.74) | |
Capex per Share |
(0.38) | (0.13) | (0.02) | (0.06) | |
Capex to Sales |
0.13 | 0.04 | 0.01 | 0.03 |
Columns are period end dates